关键词： Ovarian cancer clinical trials growth factors and receptor signal transduction

Mesh ： Antineoplastic Agents / pharmacology therapeutic use Antineoplastic Combined Chemotherapy Protocols / adverse effects therapeutic use Clinical Trials as Topic ErbB Receptors / antagonists & inhibitors Female Humans Molecular Targeted Therapy Ovarian Neoplasms / drug therapy metabolism mortality pathology Protein Kinase Inhibitors / pharmacology therapeutic use Receptors, Platelet-Derived Growth Factor / antagonists & inhibitors Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors Treatment Outcome src-Family Kinases / antagonists & inhibitors

来  源：   DOI：10.1080/07357907.2016.1206117   PDF(Sci-hub)

Abstract：
The present systematic review summarizes current evidence regarding the mechanisms of action, the efficacy, and the adverse effects of tyrosine kinase inhibitors (TKIs) in ovarian cancer patients. Phase II and III clinical trials were sought in the PubMed database and in the Clinical Trials.gov registry through September 30, 2015. Seventy-five clinical trials regarding TKIs targeting mainly vascular endothelial growth factor receptor, epidermal growth factor receptor, platelet-derived growth factor receptor, and sarcoma tyrosine kinase (Src) were yielded. The most promising results were noted with cediranib, nintedanib, and pazopanib. However, drawing universal conclusions about the potential integration of TKIs in ovarian cancer therapy remains elusive. Furthermore, emerging challenges and directions for the future research are critically discussed.
摘要：
暂无翻译
公众号